Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zavabresib - Opna Bio

Next Previous
Drug Profile

Zavabresib - Opna Bio

Alternative Names: OPN-2853; PLX-2853

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Daiichi Sankyo Company; Opna Bio; University of Birmingham
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Myelofibrosis
  • Discontinued Acute myeloid leukaemia; Graft-versus-host disease; Gynaecological cancer; Haematological malignancies; Myelodysplastic syndromes; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 21 Jan 2026 Zavabresib - Opna Bio receives Orphan Drug status for Myelofibrosis in USA
  • 08 Dec 2025 Efficacy data from the phase I PROMise trial in Myelofibrosis released by Opna Bio
  • 06 Dec 2025 Efficacy and adverse events data from the phase I PROMise trial in Myelofibrosis presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top